Thomas Günther

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 11

Top Topics

Molecular Docking

Gas Chromatography

Top Venues

Pharmaceuticals (Basel, Switzerland)

EJNMMI research

Inorganic chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Nadine Holzleitner, Sebastian Fischer, Isabel Maniyankerikalam, Roswitha Beck, Constantin Lapa, Hans-Jürgen Wester, Thomas Günther
Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs. EJNMMI research 14 (1) (2024)
Nadine Holzleitner, Sebastian Fischer, Isabel Maniyankerikalam, Roswitha Beck, Constantin Lapa, Hans-Jürgen Wester, Thomas Günther
Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs. EJNMMI research 14 (1) (2024)
Sandra Deiser, Marike Drexler, Guillermo Moreno-Alcántar, Maximilian Irl, Claudia Schmidt, Thomas Günther, Angela Casini
Synthesis of 177 Lu-Labeled, Somatostatin-2 Receptor-Targeted Metalla-Assemblies: Challenges in the Design of Supramolecular Radiotherapeutics. Inorganic chemistry (2023)
Nadine Holzleitner, Thomas Günther, Amira Daoud-Gadieh, Constantin Lapa, Hans-Jürgen Wester
Investigation of the structure-activity relationship at the N-terminal part of minigastrin analogs. EJNMMI research 13 (1) (2023)
Thomas Günther, Nadine Holzleitner, Daniel Di Carlo, Nicole Urtz-Urban, Constantin Lapa, Hans-Jürgen Wester
Development of the First 18 F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety. Pharmaceutics 15 (3) (2023)
Thomas Günther, Nadine Holzleitner, Daniel Di Carlo, Nicole Urtz-Urban, Constantin Lapa, Hans-Jürgen Wester
Development of the First 18 F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety. Pharmaceutics 15 (3) (2023)
Thomas Günther, Nadine Holzleitner, Daniel Di Carlo, Nicole Urtz-Urban, Constantin Lapa, Hans-Jürgen Wester
Development of the First 18 F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety. Pharmaceutics 15 (3) (2023)
Nadine Holzleitner, Thomas Günther, Roswitha Beck, Constantin Lapa, Hans-Jürgen Wester
Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Thomas Günther, Matthias Konrad, León Stopper, Jan-Philip Kunert, Sebastian Fischer, Roswitha Beck, Angela Casini, Hans-Jürgen Wester
Optimization of the Pharmacokinetic Profile of [ 99m Tc]Tc-N 4 -Bombesin Derivatives by Modification of the Pharmacophoric Gln-Trp Sequence. Pharmaceuticals (Basel, Switzerland) 15 (9) (2022)
Nadine Holzleitner, Thomas Günther, Roswitha Beck, Constantin Lapa, Hans-Jürgen Wester
Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Nadine Holzleitner, Thomas Günther, Roswitha Beck, Constantin Lapa, Hans-Jürgen Wester
Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)